Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19

Summary

This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of RAY1216 tablets in the treatment of mild to moderate SARS-CoV-2 infection. The total study duration is up to 28 days.

Timeline

Start

2022-11-12

Primary completion

2023-01-19

Completion

2023-03-28

Outcome

Met primary endpoint

paper 251.02 h [IQR 188.95-428.68 h]) than that of Placebo (271.33 h [IQR 219.00-529.63 h], P = 0.0022, hazard ratio [HR] 1.20 PMID 38188690 ↗

release “来瑞特韦单药治疗可显著缩短至临床持续恢复时间，尤其是病毒核酸检测阳性72小时内服药和高病毒载量的亚组人群。” raynovent.com ↗

Publications

• Zhan Y, Lin Z, Liang J, Sun R, Li Y, Lin B, Ge F, Lin L, Lu H, Su L, Xiang T, Pan H, Huang C, Deng Y, Wang F, Xu R, Chen D, Zhang P, Tong J, Wang X, Meng Q, Zheng Z, Ou S, Guo X, Yao H, Yu T, Li W, Zhang Y, Jiang M, Fang Z, Song Y, Chen R, Luo J, Kang C, Liang S, Li H; other Collaborative Institutes; Zheng J, Zhong N, Yang Z. Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial. EClinicalMedicine. 2023 Dec 14;67:102359. doi: 10.1016/j.eclinm.2023.102359. eCollection 2024 Jan.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RAY1216	Small molecule	400 mg	Oral

Indications

No indication recorded.